Condition: Type 2 Diabetes · Fatty Liver · Sponsor: Seoul National University Bundang Hospital
This exploratory study will assess the efficacy of combined pioglitazone and empagliflozin therapy in improving hepatic and metabolic outcomes in patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease (MAFLD). Although each agent has shown beneficial effects individually, evidence on their combined impact on liver health is scarce. This study seeks to determine whether the combination therapy yields additive improvements in hepatic steatosis, inflammation, and fibrosis, potentially offering a new therapeutic strategy for diabetic patients with fatty liver disease.
This description comes directly from the study's public registry record.
Soo Lim Dr, MD PhD · +82-31-787-7035 · limsoo@snu.ac.kr
Minji Sohn Dr, PhD · rainbowmjs@naver.com
Always discuss trial participation with your own doctor first.
| Seoul National University Bundang Hospital | Seongnam-si, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06989723